RS5304A - Pharmaceutical compositions of amlodipine and atorvastatin - Google Patents

Pharmaceutical compositions of amlodipine and atorvastatin

Info

Publication number
RS5304A
RS5304A YU5304A YUP5304A RS5304A RS 5304 A RS5304 A RS 5304A YU 5304 A YU5304 A YU 5304A YU P5304 A YUP5304 A YU P5304A RS 5304 A RS5304 A RS 5304A
Authority
RS
Serbia
Prior art keywords
amlodipine
atorvastatin
compositions
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
YU5304A
Other languages
English (en)
Inventor
Laman Alani
Sadath Ulla Khan
Thomas Michael Macneil
Nouman Abdul-Hussain Muhammad
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of RS5304A publication Critical patent/RS5304A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Opisan je farmaceutski preparat koji sadrži dve komponente: (a) jednu komponentu koja obuhvata granulaciju atorvastatina ili njegove farmaceutski prihvaljivih soli i nosač koji uključuje agens za alkalizaciju koji gradi pH veće od 5; i (b) drugu komponentu koja sadrži amlodipin ili njegove farmaceutski prihvatljive soli i nosač koji isključuje agens za alkalizaciju koji gradi pH veće od 5, gde su dve komponente kombinovane da grade finalni preparat za čvrsti dozni oblik, kao i metode pripreme preparat, pribor za držanje takvog preparata, i metoda za lečenje angine pektoris, ateroskleroze, kombinovane hipertanzije i hiperlipidemije i/ili hiperholesterolemije, i simptoma razlika srčanog obolenja korišćenjem terapeutski efektivnih količina farmaceutskog preparata.
YU5304A 2001-07-31 2002-07-29 Pharmaceutical compositions of amlodipine and atorvastatin RS5304A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30913301P 2001-07-31 2001-07-31
PCT/IB2002/002988 WO2003011283A1 (en) 2001-07-31 2002-07-29 Pharmaceutical compositions of amlodipine and atorvastatin

Publications (1)

Publication Number Publication Date
RS5304A true RS5304A (en) 2006-10-27

Family

ID=23196829

Family Applications (1)

Application Number Title Priority Date Filing Date
YU5304A RS5304A (en) 2001-07-31 2002-07-29 Pharmaceutical compositions of amlodipine and atorvastatin

Country Status (46)

Country Link
US (2) US20030114497A1 (sr)
EP (2) EP1411923B1 (sr)
JP (3) JP4020863B2 (sr)
KR (2) KR20040032148A (sr)
CN (2) CN1617717A (sr)
AP (1) AP1745A (sr)
AR (1) AR034925A1 (sr)
AT (1) ATE385793T1 (sr)
AU (1) AU2002355680B2 (sr)
BR (1) BR0211548A (sr)
CA (1) CA2444554C (sr)
CO (1) CO5540287A2 (sr)
CR (1) CR7219A (sr)
CY (1) CY1107245T1 (sr)
DE (1) DE60225014T2 (sr)
DK (1) DK1411923T3 (sr)
DO (1) DOP2002000445A (sr)
EA (1) EA006998B1 (sr)
EC (1) ECSP044965A (sr)
ES (1) ES2298381T3 (sr)
GE (1) GEP20063926B (sr)
GT (1) GT200200158A (sr)
HN (1) HN2002000198A (sr)
HR (1) HRP20040067A2 (sr)
HU (1) HUP0401569A2 (sr)
IL (1) IL159440A0 (sr)
IS (1) IS7089A (sr)
MA (1) MA27052A1 (sr)
MX (1) MXPA04000270A (sr)
MY (1) MY137519A (sr)
NI (1) NI200200095A (sr)
NO (1) NO20040405L (sr)
NZ (1) NZ530247A (sr)
OA (1) OA13300A (sr)
PA (1) PA8551701A1 (sr)
PE (1) PE20030324A1 (sr)
PL (1) PL368519A1 (sr)
PT (1) PT1411923E (sr)
RS (1) RS5304A (sr)
SG (1) SG143982A1 (sr)
SV (1) SV2003001189A (sr)
TN (1) TNSN04022A1 (sr)
UA (1) UA79750C2 (sr)
UY (1) UY27402A1 (sr)
WO (1) WO2003011283A1 (sr)
ZA (1) ZA200400659B (sr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
JP5000502B2 (ja) 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
TW200825092A (en) * 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
NZ561486A (en) * 2005-03-15 2011-03-31 Lupin Ltd Pharmaceutical compositions of amlodipine and benazepril
ES2558799T3 (es) * 2006-03-29 2016-02-08 Kowa Company, Ltd. Agente reductor de triglicéridos y agente de mejora del hiperinsulinismo
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
KR100793321B1 (ko) * 2006-11-29 2008-01-11 사회복지법인 삼성생명공익재단 후각장애 치료 및 예방용 조성물
CN101433539A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和他汀类药物的治疗组合物
EP2070520A1 (en) * 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
WO2009116061A2 (en) * 2008-01-10 2009-09-24 Alkem Laboratories Ltd. Stable oral pharmaceutical composition comprising atorvastatin
EP2165702B1 (en) 2008-09-17 2011-11-16 Helm AG Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation
WO2010036600A1 (en) * 2008-09-24 2010-04-01 Merck Sharp & Dohme Corp. Pharmaceutical compositions of atorvastatin
WO2011152803A1 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
US9393224B2 (en) 2011-08-26 2016-07-19 Osaka University Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN109180701A (zh) * 2018-09-07 2019-01-11 中国药科大学 一种化合物2016a0c1药物组合物的共无定形物
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
CN111689922B (zh) * 2020-07-17 2022-03-15 江西施美药业股份有限公司 一种苯磺酸左旋氨氯地平环合杂质的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
DK0680320T3 (da) * 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO1997016184A1 (en) * 1995-11-02 1997-05-09 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
YU2700A (sh) * 1997-08-29 2002-06-19 Pfizer Products Inc. Farmaceutska kombinacija koja obuhvata amlodipin i statin jedinjenja
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
KR20050086975A (ko) * 1997-11-25 2005-08-30 워너-램버트 캄파니 엘엘씨 지단백질 산화의 억제
CZ20013793A3 (cs) * 1999-04-23 2002-05-15 R. Preston Mason Farmaceutický prostředek obsahující amlodipin, způsob léčby a způsob sniľování krevního tlaku
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
US6835742B2 (en) * 2000-08-04 2004-12-28 R. Preston Mason Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release

Also Published As

Publication number Publication date
NZ530247A (en) 2006-06-30
TNSN04022A1 (fr) 2006-06-01
NO20040405L (no) 2004-03-08
EP1411923B1 (en) 2008-02-13
DE60225014T2 (de) 2008-06-12
SG143982A1 (en) 2008-07-29
PL368519A1 (en) 2005-04-04
UY27402A1 (es) 2003-02-28
ECSP044965A (es) 2004-03-23
AU2002355680B2 (en) 2007-11-15
JP2005501051A (ja) 2005-01-13
GEP20063926B (en) 2006-09-25
SV2003001189A (es) 2003-03-18
US20050107446A1 (en) 2005-05-19
IL159440A0 (en) 2004-06-01
OA13300A (en) 2007-04-13
IS7089A (is) 2003-12-22
CN101185646A (zh) 2008-05-28
DK1411923T3 (da) 2009-01-05
AR034925A1 (es) 2004-03-24
DE60225014D1 (de) 2008-03-27
CN1617717A (zh) 2005-05-18
JP2007153908A (ja) 2007-06-21
JP2007314566A (ja) 2007-12-06
KR100674762B1 (ko) 2007-01-25
CR7219A (es) 2004-03-24
CO5540287A2 (es) 2005-07-29
CA2444554A1 (en) 2003-02-13
NI200200095A (es) 2004-06-07
MA27052A1 (fr) 2004-12-20
EA200400028A1 (ru) 2004-08-26
GT200200158A (es) 2003-05-15
DOP2002000445A (es) 2003-01-31
MY137519A (en) 2009-02-27
MXPA04000270A (es) 2004-05-04
BR0211548A (pt) 2004-07-13
ATE385793T1 (de) 2008-03-15
KR20060054495A (ko) 2006-05-22
PE20030324A1 (es) 2003-04-03
HN2002000198A (es) 2005-10-20
PA8551701A1 (es) 2003-02-14
HRP20040067A2 (en) 2005-02-28
PT1411923E (pt) 2008-04-02
EP1411923A1 (en) 2004-04-28
EP1852116A1 (en) 2007-11-07
AP1745A (en) 2007-05-30
WO2003011283A1 (en) 2003-02-13
AP2004002963A0 (en) 2004-03-31
JP4020863B2 (ja) 2007-12-12
US20030114497A1 (en) 2003-06-19
HUP0401569A2 (hu) 2004-12-28
UA79750C2 (en) 2007-07-25
KR20040032148A (ko) 2004-04-14
CA2444554C (en) 2007-09-04
CY1107245T1 (el) 2012-11-21
EA006998B1 (ru) 2006-06-30
ZA200400659B (en) 2005-04-28
ES2298381T3 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
AP1745A (en) Pharmaceutical compositions of amlodipine and atorvastatin.
ME00545B (me) Terapeutske kombinacije koje sadrže amlodipin i atorvastatin
NO20002133L (no) Oppløsninger og dispersjoner i fast tilstand av svakt vannoppløselige legemidler
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
HUP0004318A2 (hu) Atorvastatint és egy vérnyomáscsökkentő szert tartalmazó gyógyszerkészítmény
EE9600072A (et) Uudne ravimsegu, mis sisaldab ACE inhibiitorit ramipriili ja dihüdropüridiinühendit
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
IL143545A (en) Thrombin inhibitors and pharmaceutical compositions containing them
IL145430A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
DK0828724T3 (da) 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
WO2003070163A3 (en) Prostacyclin derivatives for treating cancer
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
AP2001002345A0 (en) Mutual prodrugs of amlodipine and atorvastatin.
TW200503689A (en) Pharmaceutical compositions of atorvastatin
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
WO1999023070A8 (en) N-acetylserotonin derivatives and uses thereof
DE69824410D1 (en) Antithrombosemittel
BR9908155A (pt) Composto, composição farmacêutica, uso do composto, e, processo para intensificar cognição em um sujeito sofrendo de cognição diminuìda
DE69632352D1 (de) Inositolderivate und diese enthaltende pharmazeutische zusammensetzungen